Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.430
0.00 (0.00%)
At close: Feb 11, 2026, 4:00 PM EST
1.440
+0.010 (0.69%)
After-hours: Feb 11, 2026, 7:27 PM EST
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $21.19M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $51.13M, up 406.67% year-over-year. In the year 2024, Autolus Therapeutics had annual revenue of $10.12M with 496.00% growth.
Revenue (ttm)
$51.13M
Revenue Growth
+406.67%
P/S Ratio
7.44
Revenue / Employee
$78,658
Employees
650
Market Cap
380.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.12M | 8.42M | 496.00% |
| Dec 31, 2023 | 1.70M | -4.66M | -73.30% |
| Dec 31, 2022 | 6.36M | 4.03M | 172.96% |
| Dec 31, 2021 | 2.33M | 615.00K | 35.86% |
| Dec 31, 2020 | 1.72M | -1.19M | -41.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Entrada Therapeutics | 61.52M |
| Bicycle Therapeutics | 28.34M |
| Aclaris Therapeutics | 15.74M |
| Absci | 2.82M |
| Allogene Therapeutics | 22.00K |
AUTL News
- 7 days ago - Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Autolus Therapeutics Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Net Product Revenue, Pipeline Advancements and Outlook for 2026 - GlobeNewsWire
- 5 weeks ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell ShuttleTM Platform - Business Wire
- 5 weeks ago - Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL® (obe-cel) on the Cellares Cell Shuttle™ Platform - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - Autolus Therapeutics Appoints Ryan Richardson to Board of Directors - GlobeNewsWire
- 2 months ago - Why Is Autolus Therapeutics Stock Trading Higher On Tuesday? - Benzinga